[1] Morita Y, Kashima K, Suzuki M, et al.Differential diagnosis between oral metastasis of renal cell carcinoma and salivary gland cancer[J]. Diagnostics (Basel), 2021, 11(3): 506-519. [2] Gopan G, Kamala LH, Radhakrishnan N.Renal cell carcinoma presenting as bulky parotid mass case report and review of literature[J]. Indian J Surg Oncol, 2021, 12(Suppl 2): 378-382. [3] Rini BI, Campbell SC, Escudier B.Renal cell carcinoma[J]. Lancet, 2009, 373(9669):1119-1132. [4] Wolff I, May M, Hoschke B, et al.Do we need new high-risk criteria for surgically treated renal cancer patients to improve the outcome of future clinical trials in the adjuvant setting? results of a comprehensive analysis based on the multicenter CORONA database[J]. Eur J Surg Oncol, 2016, 42(5): 744-750. [5] Belli C, Trapani D, Viale G, et al.Targeting the microenvironment in solid tumors[J]. Cancer Treat Rev, 2018, 65: 22-32. [6] Hinshaw DC, Shevde LA.The tumor microenvironment innately modulates cancer progression[J]. Cancer Res, 2019, 79(18): 4557-4566. [7] Schiavoni V, Campagna R, Pozzi V, et al.Recent advances in the management of clear cell renal cell carcinoma: novel biomarkers and targeted therapies[J]. Cancers (Basel), 2023, 15(12): 3207. [8] Singla N, Ghandour RA, Margulis V.Is cytoreductive nephrectomy relevant in the immunotherapy era?[J]. Curr Opin Urol, 2019, 29(5): 526-530. [9] Makhov P, Joshi S, Ghatalia P, et al.Resistance to systemic therapies in clear cell renal cell carcinoma: mechanisms and management strategies[J]. Mol Cancer Ther, 2018, 17(7): 1355-1364. [10] Labriola MK, Batich KA, Zhu J, et al.Immunotherapy is changing first-line treatment of metastatic renal-cell carcinoma[J]. Clin Genitourin Cancer, 2019, 17(3): e513-e521. [11] Dudani S, de Velasco G, Wells JC, et al. Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival[J]. JAMA Netw Open, 2021, 4(1): e2021869. |